IGF2 and cervical carcinoma: It is possible that aberrant methylation in some CpGs in the IGF2/H19 imprinted domain such as the intron 3 CTCF site may be influencing loss of imprinting and the exclusive usage of IGF2 promoter 1, inducing IGF2 overexpression, as has been previously shown in cervical carcinomas [30].